Related Experiment Video
Updated: May 25, 2025
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Higher vasoactive usage despite hemodynamic goals is associated with higher mortality in acute myocardial
Jorge A Ortega-Hernández1, Héctor González-Pacheco1, Diego Araiza-Garaygordobil1
1Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Tlalpan, Ciudad De México, México.
Insights
Using more than two vasoactive drugs in acute myocardial infarction with cardiogenic shock (AMI-CS) significantly increases in-hospital mortality. Achieving hemodynamic goals did not mitigate this increased risk, highlighting the need for careful drug selection.
Area of Science:
- Cardiology
- Critical Care Medicine
- Pharmacology
Background:
- Cardiogenic shock (CS) is a life-threatening complication of acute myocardial infarction (AMI) with high mortality rates.
- Limited research exists on the optimal selection and use of vasoactive agents in managing AMI-CS.
- This study examines the impact of vasoactive drug regimens on in-hospital outcomes for patients with AMI-CS.
Purpose of the Study:
- To investigate the association between the number of vasoactive drugs used and in-hospital mortality in patients with AMI-CS.
- To analyze the impact of vasoactive drug choices on hemodynamic parameters and survival.
- To evaluate whether achieving hemodynamic goals influences mortality risk in patients receiving multiple vasoactives.
Main Methods:
- Retrospective analysis of 309 patients with AMI-CS who underwent pulmonary artery catheterization (2006-2021).
- Patients categorized into groups based on the number of vasoactive drugs used (0-1, 2, or >2).
- Clinical data, 24-hour hemodynamic monitoring, and logistic regression were used to assess outcomes and mortality probabilities.
Main Results:
- Patients receiving >2 vasoactive drugs exhibited significantly increased in-hospital mortality (adjusted Hazard Ratio [HRadj] = 4.62).
- Achieving hemodynamic goals did not reduce mortality in patients receiving >2 vasoactives (HRadj = 7.18).
- Vasopressin and levosimendan were associated with higher early mortality, though this effect diminished over time.
Conclusions:
- A significant correlation exists between the number of vasoactive drugs and in-hospital mortality in AMI-CS.
- The use of >2 vasoactive agents is linked to adverse outcomes, irrespective of hemodynamic goal achievement.
- Further research is warranted to explore optimal vasoactive strategies and the role of early mechanical circulatory support in AMI-CS.
Background:
Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI) with high mortality. Few studies have examined the selection and subsequent choice of vasoactive agents in CS. This study investigates the impact of vasoactive drug use and in-hospital outcomes among AMI-CS.
Materials And Methods:
A total of 309 patients who underwent pulmonary artery catheterization between 2006 and 2021 were categorized by the number of vasoactive drugs used (0-1, 2, or >2). Clinical and 24 h hemodynamic data were analyzed. Primary outcomes explored the correlation between vasoactive use and in-hospital mortality. Secondary analyses assessed hemodynamic changes and estimated mortality probabilities at different intervals using logistic regression.
Results:
In total, 57 patients received 0-1, 76 received 2, and 176 received >2 vasoactive drugs. The median age was 61 years; most were men (82%), and 82.8% had ST-segment elevation myocardial infarction. End-organ function showed progressive deterioration with escalating vasoactive use. Survival analysis revealed an increased mortality in the >2 vasoactive group [HRadj = 4.62 (2.07-10.32)], achieving ≥5/6 hemodynamic goals that did not mitigate mortality [HRadj = 7.18 (1.59-32.39)]. Subgroup analyses within patients who reached different hemodynamic goals reiterated adverse outcomes associated with >2 vasoactives (P < 0.05). Further analysis showed that vasopressin was associated with the highest mortality in a time-dependent fashion [HRDay1, 8.77 (6.04-12.75) → HRDay30, 1.23 (0.8-1.87)], and levosimendan had similar behavior [HRDay1, 2.67 (1.82-3.91) → HRDay30, 0.66 (0.42-1.03)].
Conclusions:
A significant association between the number of vasoactives and in-hospital mortality was found in AMI-CS, which requires future long-term studies to explore the role of vasoactive drug therapies and early temporary mechanical circulatory support.
Related Concept Videos
01:24Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:26Heart Failure Drugs: Inotropic Agents
01:23Antihypertensive Drugs: Vasodilators
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....